Physician Adoption of Live Video Detailing Has Doubled Since 2008

Manhattan ResearchLive video detailing has made a strong comeback after a false start in the early 2000s, according to pharmaceutical and healthcare market research company Manhattan Research's ePharma Physician® v10.0 study. Physician adoption of live video detailing has more than doubled in the past two years, according to the study. A considerable share of these users self-report that their prescribing behavior is influenced by these programs, which is critical feedback for marketers concerned about the return on investment of this channel.

"Live video detailing is certainly a success story so far, which is great news for companies looking to optimize their sales strategy," said Monique Levy, Senior Director of Research at Manhattan Research. "After this initial surge in participation, however, we expect adoption will likely plateau for the next few years while companies do a better job at relaying the value proposition and optimize targeting to non-users."

Complimentary Recorded Webinar
ePharma Physician® provides key intelligence to pharma and biotech companies, agencies, and healthcare publishers connecting with physicians through digital channels. The study provides in-depth data and analysis on video detailing, including reach and satisfaction rankings of e-detailing and video detailing programs by company. Additional research topics include the physician channel mix, iPad use and interest, relationship with reps, various types of online promotion, visitation to online pharmaceutical properties, customer service, electronic sampling, and much more.

For an overview of ePharma Physician® research topics and subscription benefits in a complimentary recorded webinar, please visit http://www.manhattanresearch.com/webinars/epp.

About ePharma Physician®
ePharma Physician® v10.0 was conducted via online survey in Q2 2010 among 1,713 U.S. physicians who have looked online for pharmaceutical information, visited a pharmaceutical or biotech product or corporate website, or participated in an e-detailing program from a pharmaceutical or biotech company in the past 12 months. Clients can cut the data to gain insights for more than 25 specialties.

For additional information, please visit http://www.manhattanresearch.com/epp.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a global pharmaceutical and healthcare market research and strategic advisory firm and conducts annual research studies covering eHealth trends among physicians and consumers. Broad consumer and physician research is complemented by analysis for over 100 consumer therapeutic segments and physician specialist segments. For more information, please contact This email address is being protected from spambots. You need JavaScript enabled to view it. or visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresourcesinc.com.

Most Popular Now

Pfizer and Lilly announce top-line results from lo…

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of the stu...

Bristol-Myers Squibb reports first quarter financi…

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2019 which were highlighted by strong demand for Opdivo (nivolumab) and Eliquis (a...

Walnuts may help lower blood pressure for those at…

When combined with a diet low in saturated fats, eating walnuts may help lower blood pressure in people at risk for cardiovascular disease, according to a new Penn State ...

Amgen ignites a social fitness movement to support…

Amgen (NASDAQ:AMGN) launched the Breakaway Challenge initiative, a national social fitness program to motivate individuals to take action in their health and to support t...

Comprehensive tumor profiling promises new therape…

The WINTHER trial, NCT01856296, led by investigators from Vall d'Hebron Institute of Oncology - VHIO (Spain), Chaim Sheba Medical Center (Israel) (Raanan Berger), Gustave...

AstraZeneca starts artificial intelligence collabo…

AstraZeneca and BenevolentAI today began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treat...

Possible link between autism and antidepressants u…

An international team led by Duke-NUS Medical School has found a potential link between autistic-like behaviour in adult mice and exposure to a common antidepressant in t...

Chemotherapy or not?

Case Western Reserve University researchers and partners, including a collaborator at Cleveland Clinic, are pushing the boundaries of how "smart" diagnostic-imaging machi...

Researchers define Alzheimer's-like brain disorder

A brain disorder that mimics symptoms of Alzheimer's disease has been defined with recommended diagnostic criteria and guidelines for advancing future research on the con...

Drugs to prevent stroke and dementia show promise …

Treatments that prevent recurrence of types of stroke and dementia caused by damage to small blood vessels in the brain have moved a step closer, following a small study...

Amgen and Syapse enter precision medicine collabor…

Amgen (NASDAQ:AMGN), a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, announced a precisio...

Personalizing precision medicine with combination …

Precision oncology often relies on treating patients with a single, molecularly matched therapy that targets one mutation in their tumor. In a report, published online in...